Recurrent Lymphoma Active Not Recruiting Phase 2 Trials for Selpercatinib (DB15685)

IndicationStatusPhase
DBCOND0073930 (Recurrent Lymphoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04320888Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialTreatment